fda statement on compounded semaglutide How Crackdowns Are Affecting GLP-1 Use In 2025 Novo Nordisk calls out dangers

[Glutathione, glutathione peroxidase (GPx), glutathione S-transferase (GST)]

By increasing Akkermansia and Bifidobacterium populations through resistant starch feeding, and by supporting gut barrier integrity through postbiotics, the supplement aims to create a gut environment that consistently produces more GLP-1 in response to meals

It requires a holistic approach that includes dietary consistency, regular physical activity, psychological support, and ongoing medical monitoring

In October 2024, Novo Nordisk formally asked the FDA to ban the production of compounded semaglutide and requested that the agency move the drug to its Demonstrable Difficulties for Compounding (DDC) list

The unique formulation includes critical cofactors that many people are missing: selenium to activate your glutathione peroxidase (GPX) enzyme, riboflavin to recycle used glutathione via your glutathione reductase (GSR) enzyme, molybdenum to support your sulfite oxidase (SUOX) enzyme and prevent the uncomfortable side effects some people experience from glutathione

But the program focuses on three: Orforglipron (Foundayo), a once-daily tablet that can be taken by mouth without food or water and in clinical trials led to an 11% weight reduction in 16 months